Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

Biochemical recurrence-free survival in prostate cancer improves after WPRT

12 Jan 2020

Whole-pelvis radiotherapy (WPRT) improves biochemical recurrence-free survival (bRFS), but not distant metastasis-free survival (DMFS) and prostate cancer-specific survival (PCSS), in patients with Gleason grade group 5 prostate cancer (PCa) treated with either external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT), a recent study has found.

The study included 1,170 eligible PCa patients, of whom 734 (median age, 68 years) received EBRT alone and 436 EBRT+BT (median age, 68 years). Study outcomes were bRFS, DMFS and PCSS, which were compared between groups after propensity score adjustments.

More than half (53 percent; n=619) of the patients received WPRT. Kaplan-Meier curves, adjusted for potential covariates, showed that in the EBRT group, the adjusted 5-year bRFS rates in patient with vs without WPRT were 66 percent and 58 percent, respectively. In the EBRT+BT patients, the corresponding rates were 88 percent and 78 percent.

In the propensity score-adjusted model, WPRT provided a significant benefit in the EBRT+BT patients (hazard ratio [HR], 0.5, 95 percent confidence interval [CI], 0.2–0.9; p=0.02), but not in those who received EBRT alone (p=0.4).

The opposite was true for DMFS, which did not show signs of benefit from WPRT in either the EBRT alone (HR, 1.1, 95 percent CI, 0.7–1.7; p=0.8) or EBRT+BT (HR, 0.6, 95 percent CI, 0.3–1.4; p=0.2) treatment groups.

PCSS, likewise, derived no significant benefit from WPRT (EBRT alone: HR, 0.7, 95 percent CI, 0.4–1.1; p=0.1; EBRT+BT: HR, 0.5, 95 percent CI, 0.2–1.2; p=0.1).

Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.